summari ew report underli revenu
underli beat consensu
estim adj ep also came ahead
consensu estim top-lin beat
driven robust top-lin growth
lead ew thvt
transcathet heart valv therapi busi strength
us ou outsid us region ew underli global
thv transcathet heart valv sale
includ consumpt stock inventori
consensu
expect respect wed note
sale figur referenc note underli basi
adjust stock pipelin front notabl
develop view ew expect centera receiv
ce mark approv later month sapien ultra still
expect receiv ce mark fda approv late
term outlook ew rais top-lin guidanc
higher-end rang increas adj ep
guidanc report wed note
given momentum strengthen euro ew rais
guidanc three busi high-end
heart valv critic cc
ew guid total sale
report adj ep report
estim chang rais sale estim
ex-fx adj ep estim
report rais sale
estim report adj ep
estim report rais price
target assum adj
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
compani prioriti stock list
compani data secur llc estim reuter
top-lin driven balanc tavr growth underli us thv sale
top estim manag said growth us reflect robust therapi
adopt us sitesparticularli lower volum center smaller expect impact
decemb holiday ew believ growth roughli line broader market ew
report outsid us ou thv sale underli ahead estim
europ ew post strong quarter estim y/i ahead prior
expect aid part rel easi prior year compar recal ew
incur approxim hit reimburs cap franc japan tavr transcathet
aortic valv replac growth remain robust -- estim ew japan tavr sale
get insight ou market dynam report
earn februari ew rais full-year thv guidanc higher-end
dollar rang higher-end underli growth guidanc
centera expect receiv ce mark approv februari notabl pipelin updat
view announc centera expect receiv ce mark approv later month
believ centera well sapien ultra potenti meaning growth driver ew
beyond manag said excit launch given devic impress clinic
data differenti product featur ew plan target tavr implant prefer self-expand
devic price valv premium competit product similar sapien manag
plan initi us pivot trial centera point year regard sapien ultra ew still
expect receiv ce mark approv fda approv late
transcathet mitral tricuspid updat today call ew help frame
expect cardioband mitral repair devic europ ew expect modest cardioband commerci
sale sale ramp throughout full-year addit manag
provid sever updat transcathet mitral tricuspid program notabl updat
follow harpoon ce mark approv european launch expect pascal
clasp ce mark trial expect finish enrol put launch time track us
pascal studi schedul begin ew activ us pivot trial remain on-going cardioband
mitral posit ew receiv approv begin cardioband tricuspid us earli feasibl
studi european approv remain track year-end addit manag said
encourag earli clinic progress made transcathet mitral valv
replac tmvr devic cardiaq sapien
intuiti elit continu drive shv growth ew report shv surgic heart valv sale
underli sequenti deceler vs growth result
driven strong unit growth across region share gain new product primarili intuiti elit
manag note adopt intuiti elit strong benefit new tech add-
payment award center medicar medicaid servic went effect
octob ew said seen increas util new center adopt
separ ew said interest inspiri resilia valv increas europ ew launch
inspiri us past month still expect launch japan later year provid
reimburs place manag re-affirmed underli growth expect shv
busi expect shv sale come toward higher-end
critic see meaning acceler ew report critic cc sale
underli beat consensu estim cc growth repres
meaning sequenti acceler underli growth result quarter
driven strong broad base growth across busi sale particularli strong apac
doubl digit hospit custom util portion respect year-end
capit budget addit ew continu expans enhanc surgic recoveri esr
program particularli clearsight us china roll-out ew hemospher advanc
monitor platform remain on-going manag expect hemospher import growth
driver long-term ew reiter critic care underli growth guidanc
guid toward higher-end previous commun sale guidanc rang
outlook rais guidanc introduc call ew rais guidanc
provid investor day past decemb manag expect total sale come
toward higher-end guidanc rang adj ep guidanc increas
report ew elect rais outlook given strong momentum
busi improv fx rate busi manag expect sale dollar
basi high-end previou guidanc rang thv ew expect sale
higher-end dollar rang higher-end underli growth guidanc shv
critic ew expect sale higher-end underli
underli rang respect ew reiter guidanc
 item gross margin sg dilut share count
notabl ew formal lower tax rate guidanc lower
previou estim use midpoint includ tax rate guidanc
estim benefit chang stock base compens account rule ew
guid total sale report adj ep
price target
price target assum ep estim risk includ greater
share loss model delay mitral program neg clinic data
believ upcom data pipelin product help ew address new competit
transcathet mitral valv opportun signific catalyst
irvin california -base edward lifesci ew develop manufactur market product
design heart valv diseas cardiac surgeri critic care edward revenu reach
billion come transcathet heart valv therapi thv busi ew
player transcathet heart valv therapi market
edward lifesci -- quarterli incom statementin million except per share dataproduct line good sold excl gross gross oper oper oper expens expens incom pre-tax net dilut share amort expens exclud share count forward adjust two-for-on stock splitsourc compani report secur llc estim medic technolog
